SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Anticancer Res. 2018;38(6):3527-3533.

Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.

, , , , , , ,

제1저자 김나영, 강민정 · 교신저자 이상협

소속 (4)
  1. Department of Convergence Medicine & Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  2. Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea gidoctor@snuh.org.
  3. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.
  4. Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

Abstract

BACKGROUND Pancreatic cancer is a highly lethal malignancy with a poor prognosis. This study was set up to investigate the combined effect of gemcitabine and fisetin, a natural flavonoid from plants, on human pancreatic cancer cells. Meterials and Methods: Cytotoxic effect of fisetin in combination with gemcitabine on MiaPaca-2 cells was evaluated by the MTT assay, caspase 3/7 assay and propidium iodide/Annexin V. Extracellular signal-regulated kinase (ERK)-v-myc avian myelocytomatosis viral oncogene homolog (MYC) pathway was investigated by western blotting and quantitative real-time polymerase chain reaction.

RESULTS Combination treatment with fisetin and gemcitabine inhibited the proliferation of pancreatic cancer cells within 72 h and induced apoptosis, as indicated by activation of caspase 3/7. Fisetin down-regulated ERK at the protein and mRNA levels, and reduced ERK-induced MYC instability at the protein level.

CONCLUSION Fisetin sensitized human pancreatic cancer cells to gemcitabine-induced cytotoxicity through inhibition of ERK-MYC signaling. These results suggest that the combination of fisetin and gemcitabine could be developed as a novel potent therapeutic.

Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Keywords

Fisetincombination therapygemcitabinepancreatic cancer

그 밖의 정보
출판 형태
Journal Article
저널
Anticancer research · eISSN 1791-7530
MeSH
Antimetabolites, Antineoplastic / pharmacology · Apoptosis / drug effects · Caspase 3 / metabolism · Caspase 7 / metabolism · Cell Line, Tumor · Cell Proliferation / drug effects · Cell Survival / drug effects · Deoxycytidine / analogs & derivatives / pharmacology · Down-Regulation / drug effects · Drug Synergism · Extracellular Signal-Regulated MAP Kinases / genetics / metabolism · Flavonoids / pharmacology · Flavonols · Humans · Pancreatic Neoplasms / genetics / metabolism / pathology · Proto-Oncogene Proteins c-myc / metabolism · Gemcitabine
Substances
Antimetabolites, Antineoplastic · Flavonoids · Flavonols · MYC protein, human · Proto-Oncogene Proteins c-myc · Deoxycytidine · Extracellular Signal-Regulated MAP Kinases · CASP3 protein, human · Caspase 3 · Caspase 7 · fisetin · Gemcitabine